CDEK
← All drugs Report issue

furazolidone

Trade name: furoxone

Small moleculeapproved

Approved

Jan 20, 1958

Furazolidone is a nitrofuran derivarive with broad antibacterial, antiprotazoal properties. It was used for the treatment of bacterial or protozoal enteritis and diarrhea, but now the drug is no longer prescibed in the US. The mechanism of furazolidone action is supposed to be mediated by its binding to bacterial DNA. — NCATS

Clinical trial activity

35 trials · 23 clinical orgs · 1 marketing orgs

Phase 1
3
Phase 2
2
Phase 3
1
Phase 4
23

Earliest trial started Oct 1, 2006 (NCT00520949)

Timeline

1950s

  1. Jan 20, 1958

    Shire — Earliest FDA Approval

  2. Jan 20, 1958

    Shire — NDA Secondary Org

  3. Jan 20, 1958

    Shire — NDA Organization

2000s

  1. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • DNAINHIBITOR

    DNA inhibitor

    Promotes inter-strand DNA cross-linking

Approval history

  • approvedJan 20, 1958

Chemistry & pharmacology

Loading structure…

SMILES

[O-][N+](=O)C1=CC=C(O1)\C=N\N2CCOC2=O
Mol. weight
225.1583 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
  • 3-{[(5-nitro-2-furanyl)methylene]amino}-2-oxazolidinone
  • 3-(5'-nitrofurfuralamino)-2-oxazolidone
  • 3-(5'-nitrofurfuralamino)-2-oxazolidone
  • 3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
  • 3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
  • 3-[(5-nitrofurfurylidene)amino]-2-oxazolidone
  • 3-[(5-nitrofurfurylidene)amino]-2-oxazolidone
  • 3-[(5-nitrofurylidene)amino]-2-oxazolidone
  • 3-[(5-nitrofurylidene)amino]-2-oxazolidone
  • 5-nitro-n-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
  • 5-nitro-n-(2-oxo-3-oxazolidinyl)-2-furanmethanimine
  • diafuron
  • furall
  • furall
  • furaxone
  • furazol
  • furazolidinone
  • furazolidon
  • furazolidona
  • furazolidona
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidone
  • furazolidonum
  • furazolidonum
  • furazon
  • furidon
  • furoxone
  • furoxone
  • furoxone
  • furoxone
  • fzl
  • fzl
  • n-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone
  • n-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone
  • n-(5-nitro-2-furfurylidene)-3-aminooxazolidine-2-one
  • n-(5-nitro-2-furfurylidene)-3-aminooxazolidine-2-one
  • nifurazolidone
  • nifurazolidone
  • nitrofurazolidone
  • nitrofurazolidone
  • nitrofurazolidone
  • nitrofurazolidonum
  • nitrofurazolidonum
  • nitrofuroxon

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07139366Phase 4Sep 30, 2025People's Liberation Army of China
NCT06777732Early Phase 1 (Phase 1)Mar 31, 2025Nanjing Medical University
NCT06168214Phase 4Sep 4, 2023People's Liberation Army of China
NCT06168084Phase 4Jun 6, 2023People's Liberation Army of China
NCT05718609Phase 4Mar 1, 2023Zhejiang University
NCT05586464Phase 1Nov 1, 2022Liaocheng People's Hospital
NCT06823791Phase 1/Phase 2 (Phase 2)Aug 1, 2022Liaocheng People's Hospital
NCT05345210Phase 4Apr 25, 2022People's Liberation Army of China
NCT05191875N/ADec 1, 2021Central South University
NCT05135182Phase 4Nov 28, 2021Shandong University
NCT04991584N/AAug 4, 2021Shandong University
NCT05097846N/AJun 17, 2021Central South University
NCT04907747Phase 4May 18, 2021Zhejiang University
NCT05410223N/AApr 6, 2021Central South University
NCT05176821N/AJan 1, 2021Fudan University
NCT04678492Phase 4Dec 20, 2020People's Liberation Army of China
NCT04034641Phase 4Nov 1, 2019Hangzhou Grand Biologic Pharmaceutical, Inc., Jiao Tong University, Nanchang University, Nanjing Medical University, People's Liberation Army of China, Wuhan University, Zhejiang Chinese Medical University, Zhejiang University, Zhengzhou University
NCT04264663Phase 4Nov 1, 2019Shandong University
NCT03726099Phase 4Mar 15, 2019Shandong University
NCT03658746Phase 4Oct 1, 2018Shandong University
Showing 20 of 35 trials
Page 1 / 2

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Shandong UniversityAcademic/Hospital121222017
People's Liberation Army of ChinaGovernment9622016
Zhejiang UniversityAcademic/Hospital5422016
Central South UniversityAcademic/Hospital4422017
Jiao Tong UniversityAcademic/Hospital3222012
Liaocheng People's HospitalAcademic/Hospital3232017
Nanjing Medical UniversityAcademic/Hospital3132016
Aga Khan UniversityAcademic/Hospital1112006
Binzhou Medical UniversityAcademic/Hospital1012017
Centers for Disease Control and Prevention, ChinaGovernment1012016
Fudan UniversityAcademic/Hospital1112021
Fundação de Amparo à Pesquisa do Estado de São PauloAcademic/Hospital1012008
Hangzhou Grand Biologic Pharmaceutical, Inc.Government1112019
Livzon Pharmaceutical Group Inc.For profit1012017
Nanchang UniversityAcademic/Hospital1012019
Shandong Provincial HospitalAcademic/Hospital1012017
Southern Medical UniversityAcademic/Hospital1012016
Tsinghua UniversityAcademic/Hospital1012016
University of Sao PauloAcademic/Hospital1112008
Wuhan UniversityAcademic/Hospital1012019
23 organizations
Page 1 / 2

Marketing (2)

OrganizationOrg typeRelationshipDate
ShireFor profitNDA2Jan 20, 1958
ShireFor profitNDAJan 20, 1958